Attention COVID-19 Survivors: You beat it. Now you could help fight it.
Visit TheFightIsInUs.org now to learn more about the urgent need for you to donate your strength — donate your plasma.
Close

COVID-19 update: As you navigate challenges due to the COVID-19 outbreak, know that we are here for you. Please contact OnePath® with questions about accessing your Takeda HAE treatment and for additional product support. For updates from Takeda, click here.

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

REIMAGINE YOUR LIFE WITH HAE

TAKHZYRO is a first-of-its-kind medicine used to prevent
attacks of hereditary angioedema (HAE) in people 12 years of
age and older.

See What's Possible

See Lexi's
Reimagine Story

Down arrow icon

Reimagine your life with fewer attacks

Fewer attacks or zero attacks in a study

People taking TAKHZYRO in a clinical study had HAE
attacks less often, and some people in the study had zero
attacks. Want to see the study details? We’d love to share.

In a 26-week clinical trial of 125 people with HAE 12 years of age and older,
TAKHZYRO significantly reduced the number of monthly attacks, compared
with placebo. People taking TAKHZYRO also had fewer moderate or severe
attacks and fewer attacks requiring acute treatment, compared with
placebo. And according to a supportive analysis, there were people taking
TAKHZYRO who had zero attacks during the entire clinical trial.

More Study Info

See Marie's
Reimagine Story

Reimagine your
dosing schedule

TAKHZYRO is a subcutaneous (under-the-skin)
injection you give yourself once every 2 weeks
after being trained by a healthcare provider.

GET DOSING INFO HERE

The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO. If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg every 4 weeks.

See what made patients
want to start TAKHZYRO

Speech bubbles icon

Ready to ask your doctor about TAKHZYRO?

Curious about what TAKHZYRO could do for you? Ask
your doctor. You can use our discussion guide to help
get the conversation started.

start your guide

OnePath® icon

Personalized product support every step of the way

OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • fast heartbeat
  • faintness
  • rash
  • hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see full Prescribing Information, including information for patients.